Fig. 6
Role of intrinsic PD-1 in tumorigenicity of TC cells. a. Tumour growth of pCMV3- (a mass population) or PD-1-transfected (mean of 2 clones) 8505c cells. b. Proliferation index (Ki-67), apoptotic rate (cleaved caspase 3), and vessel density (CD31) assessed by immunohistochemistry of 8505c pCMV3 or pCMV3 PD-1 cell xenografts harvested 28 days post-inoculation. The relative quantifications (5 fields/sample) are shown. c. Tumour growth of 8505c xenografts in mice treated intraperitoneally (i.p.) at 30 mg/kg twice per week with Nivolumab (Nivo) or control IgG4. d. Proliferation index (Ki-67), apoptotic rate (cleaved caspase 3), and vessel density (CD31) assessed by immunohistochemistry of 8505c cell xenografts, treated with Nivoumab or IgG4, harvested 35 days post-inoculation. The relative quantifications (5 fields/sample) are shown.* P < 0.05 compared to the relative control